Kelly J. Manahan

Q: What Schools Are Affiliated With Kelly J. Manahan

Kelly J. Manahan is affiliated with the following schools: Indiana University, University of Michigan, Stanford University, Johns Hopkins University, University of Toledo, Columbia University

Kelly J. Manahan's AcademicInfluence.com Rankings

Kelly J. Manahan

Philosophy

#13012

World Rank

#18246

Historical Rank

Logic

#10074

World Rank

#12879

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Kelly J. Manahan's Degrees

Doctorate Medicine Johns Hopkins University
PhD Obstetrics and Gynecology Columbia University

Why Is Kelly J. Manahan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Kelly J. Manahan is an American gynecologist who is the current Chair of Obstetrics and Gynecology at the University of Toledo College of Medicine and Life Sciences in Toledo, Ohio. She is the fifth Chair of Obstetrics and Gynecology for The University of Toledo which is the former Medical College of Ohio. She is the first female to hold this position. She was appointed to this position after a nationwide search in 2011.

(See a Problem?)

Kelly J. Manahan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. (2006) (84)
Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. (2007) (84)
Robotically assisted total laparoscopic radical trachelectomy for fertility sparing in stage IB1 adenosarcoma of the cervix. (2008) (72)
Robotically Assisted Laparoscopic Radical Hysterectomy Compared With Open Radical Hysterectomy (2009) (68)
The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). (2005) (65)
HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. (2004) (43)
Pelvic and para‐aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium (2007) (30)
Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer. (2004) (24)
5-Millimeter Trocar-Site Bowel Herniation Following Laparoscopic Surgery (2012) (24)
Loop electrosurgical excision procedure for partial upper vaginectomy. (1999) (19)
Peritoneal fluid urea nitrogen and creatinine reference values. (1999) (19)
Imiquimod in vulvar Paget's disease: a case report. (2008) (18)
Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. (2008) (17)
Heat shock protein 27 in the placentas of women with and without severe preeclampsia. (2004) (13)
Assessment of False-negative Ascites Cytology in Epithelial Ovarian Carcinoma: A Study of 313 Patients (2017) (12)
Clonal heterogeneity of p53 mutations in ovarian cancer. (2001) (12)
Extreme drug resistance is common after prior exposure to paclitaxel. (2007) (12)
Treatment of Advanced or Recurrent Cervical Cancer with Cisplatin or Cisplatin Containing Regimens: A Cost Effective Analysis (2012) (11)
Recombinant factor VIIa to treat late radiation-induced hemorrhagic cystitis: a case report. (2008) (11)
The interaction of ifosfamide and aprepitant in gynecologic malignancies☆ (2013) (11)
Electrosurgical Settings and Vaginal Cuff Complications (2015) (11)
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND CYCLOOXYGENASE 2 (COX 2) IMMUNOSTAINING IN OVARIAN CANCER (2004) (8)
Evaluation of DNA methylation in the human genome: why examine it and what method to use. (2004) (7)
Methylation: a second hit in the two-hit hypothesis. (2003) (6)
Ovarian cancer risk assessment: a tool for preoperative assessment. (2011) (6)
Primary carcinoma of the fallopian tube and epithelial ovarian carcinoma: a case-control analysis. (2008) (6)
Increasing somatostatin analogues until effective. (2005) (6)
Chemotherapy for ovarian cancer: an evidence-based approach. (2004) (5)
An economic analysis of cisplatin alone versus cisplatin doublets in the treatment of women with advanced or recurrent cervical cancer. (2014) (4)
Modified radical vulvectomy without lymphadenectomy under local anesthesia in medically compromised patients. (1997) (4)
Cyclin E is overexpressed by clear cell carcinomas of the endometrium and is a prognostic indicator of survival. (2015) (3)
Robotically-assisted laparoscopic radical parametrectomy and radical vaginectomy. (2011) (3)
Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable? (2016) (3)
Changes in Length of Stay and 30-Day Readmission Rates After Starting an Advanced Surgical Recovery Program [24O] (2019) (3)
Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy (2016) (3)
Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival (2003) (2)
Immunohistochemical Profile of Tamoxifen-Related Uterine Adenosarcomas (2010) (2)
Total colectomy in primary ovarian cytoreduction. (2011) (2)
Annual cost of bevacizumab in the adjuvant treatment of ovarian cancer to the U.S. Medicare system (2012) (2)
5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report. (2007) (1)
Ovarian Cancer Risk Assessment: A Tool for the Preoperative Prediction of Ovarian Cancer in Women With Pelvic Masses (2006) (1)
Chemotherapeutic regimens for early high risk ovarian cancer (2012) (1)
Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel? (2004) (1)
Nuclear size, shape, and density in endometrial carcinoma (2003) (1)
Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors (2016) (1)
CA-125 and grade 1 endometrial cancer: Analyzing the risk of metastases (2016) (1)
Cost effective analysis of treatment methods used for unexplained infertility (2012) (1)
Salvage use of Y90 coated hepatic arterial beads in the treatment of liver predominant metastatic colorectal cancer: Cancer Treatment Centers of America Southeastern Region experience. (2018) (0)
Tunneled central venous catheters in a gynecologic oncology service: operative and short-term complications. (2008) (0)
Thrombocytosis is a Prognostic Factor in Women Treated with Chemoradiation for Advanced Cervical Cancer [21A] (2018) (0)
Can molecular profiling increase the ability to provide cost effective health care in gynecologic oncology (2013) (0)
Using a Panel of Immunohistochemical Stains to Determine Risk of Lymph Node Metastases in Women with Endometrioid Adenocarcinoma of the Endometrium (2011) (0)
Mutational landscape of gynecologic cancers identified by prospective clinical sequencing in a nationwide cancer network (2019) (0)
How often are residual adnexal structures identified at surgery on a gynecologic oncology service after previous bilateral salpingo-oophorectomy? (2017) (0)
Genomic Alterations Found in Recurrent Uterine Sarcomas of African-American Women [18A] (2018) (0)
Morbidity of Partial Gastrectomy in Primary Ovarian Cancer Cytoreduction (2010) (0)
Clinical effect of liver transaminase abnormalities after ablation of ovarian cancer. (2017) (0)
Cost Utility Analysis of Methotrexate Versus Actinomycin-D in Low Risk Gestational Trophoblastic Neoplasia [2J] (2017) (0)
Factors Associated with Need for Drainage of Pleural Effusion after Diaphragm Surgery (2014) (0)
Treatment of women with intermediate risk endometrial cancer (2012) (0)
Post-operative fever in open compared with robotic hysterectomies for endometrial cancer (2017) (0)
CA 125 and Grade 1 endometrial cancer: analyzing the risk of metastases (2019) (0)
Changes in length of stay and 30-day readmission rates after starting an advanced surgical recovery program (2019) (0)
Coagulopathy, Blood Loss, and Vascular Endothelial Growth Factor in Advanced Epithelial Ovarian Cancer (2006) (0)
Indication specific pricing for targeted therapies: Using bevacizumab as an example. (2018) (0)
A Case‐Control Analysis of Primary Carcinoma of the Fallopian Tube and Epithelial Ovarian Carcinoma (2003) (0)
0543: Pathologic Evaluation of Lymph Node Specimens in Gynecologic Oncology (2006) (0)
Exacerbation of Migraines Following Robotic Surgery for Endometrial Carcinoma [7P] (2016) (0)
Changes in Narcotic Use after Initiation of an Advanced Surgical Recovery Program [4J] (2019) (0)
Accuracy of Robotic Cytoreduction Estimates for Ovarian Epithelial Malignancies [33E] (2017) (0)
Exacerbation of Migraines Following Robotic Surgery for Endometrial Carcinoma (2015) (0)
Adding a molecular profile test to make use of bevacizumab more affordable in ovarian cancer (2015) (0)
Ovarian Cancer Risk Assessment (2006) (0)
0229: Increased Morbidity in Patients Undergoing Primary Suboptimal Versus Optimal Cytoreduction for Ovarian Cancer (2006) (0)
A CASE-CONTROL ANALYSIS OF PRIMARY CARCINOMA OF THE FALLOPIAN TUBE (2004) (0)
NEOADJUVANT CHEMOTHERAPY IN VULVAR CANCER: AVOIDING PRIMARY EXENTERATION (2004) (0)
Accuracy of robotic cytoreduction estimates for ovarian epithelial malignancies (2017) (0)
Potential benefit of using phenazopyridine to detect multiple vesicovaginal fistulas for primary repairs on medical mission trips in Cote d'Ivoire (2022) (0)
Determining the most effective strategy to screen women with ovarian cancer for BRCA 1/2 germline mutations (2016) (0)
0226: Nutritional Assessment Using Prealbumin As Objective Criteria to Determine Whom Can Undergo Primary Radical Cytoreductive Surgery for Ovarian Cancer (2006) (0)
Further use of liposomal doxorubicin regimen after initial dose hypersensitivity (2019) (0)
0228: Secondary Cytoreduction is Associated with More Morbidity and Mortality Than Primary or Interval Cytoreduction (2006) (0)
An economic analysis of bevacizumab in treatment of cervical cancer (2014) (0)
CA 125 and Grade 1 Endometrial Cancer: Analyzing the Risk of Metastases [22P] (2016) (0)
Decrease in narcotic use after initiation of an advanced surgical recovery program (2019) (0)

This paper list is powered by the following services:

Other Resources About Kelly J. Manahan

en.wikipedia.org

What Schools Are Affiliated With Kelly J. Manahan?

Kelly J. Manahan is affiliated with the following schools:

Kelly J. Manahan's Academic­Influence.com Rankings